FIBROBIOLOGICS INC (FBLG) Stock News
NASDAQ:FBLG - Nasdaq - US31573L1052 - Common Stock - Currency: USD
FBLG Latest News, Press Releases and Analysis
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference
FibroBiologics to Host In-Person Analyst Day to Provide Research & Development Updates
FibroBiologics to also present at the BIO CEO & Investor Conference...
Stay updated with the stocks that are on the move in today's pre-market session.
Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
FibroBiologics Closes Second $5 Million Tranche of $25 Million Financing
HOUSTON, Dec. 30, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (
FibroBiologics Announces $25 Million Financing
FibroBiologics Announces $25 Million Financing
HOUSTON, Dec. 23, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
HOUSTON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) , a clinical-stage biotechnology company with 160+ patents issued and...
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
HOUSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Preparations for Phase 1/2 clinical trial in Australia utilizing fibroblast-based spheroids product candidate, CYWC628, to treat diabetic foot ulcers are...
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
HOUSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+...
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
HOUSTON, Oct. 18, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”) and Charles River Laboratories (“Charles River”), a...
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
HOUSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics , a clinical-stage biotechnology company with 160+...
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
HOUSTON, Oct. 11, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+...
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs...
FibroBiologics Engages Southern Star Research as CRO in Australia
Southern Star Research will provide CRO services for FibroBiologics in Australia
FibroBiologics Engages Southern Star Research as CRO in Australia
Southern Star Research will provide CRO services for FibroBiologics in Australia...
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
HOUSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+...
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOUSTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+...
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+...